Andrew
04-22-03, 10:18 PM
CNS/Neurology
POSITIVE RESULTS REPORTED FOR PHASE III INSOMNIA DRUG TRIAL
Neurocrine Biosciences announced positive results of the company's second Phase III clinical trial of indiplon to treat chronic insomnia. The drug was demonstrated as safe, effective and well-tolerated in 200 adult patients with chronic primary insomnia during a 35-day period. The study showed significant results in sleep initiation with no evidence of side effects the following day.
POSITIVE RESULTS REPORTED FOR PHASE III INSOMNIA DRUG TRIAL
Neurocrine Biosciences announced positive results of the company's second Phase III clinical trial of indiplon to treat chronic insomnia. The drug was demonstrated as safe, effective and well-tolerated in 200 adult patients with chronic primary insomnia during a 35-day period. The study showed significant results in sleep initiation with no evidence of side effects the following day.